GlassScriptPhysician profile
Yazeid Alshebani
NPI 1124422936
$1,653.53
in general payments reported to CMS, 2019-2025
19 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $990 · 2021: $191 · 2022: $227 · 2023: $40.71 · 2024: $57.26 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $245.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $961.66 | 2019 | |
| Amgen INC. | $107.60 | 2021-2024 | Repatha |
| Pfizer INC. | $85.24 | 2022-2025 | |
| Chiesi USA, INC. | $81.62 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $69.41 | 2021-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $56.97 | 2022-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.79 | 2021-2023 | Jardiance |
| Esperion Therapeutics, INC. | $35.07 | 2021-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $28.72 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.43 | 2025 | Lifevest |
| Eagle Pharmaceuticals, INC. | $24.98 | 2023 | |
| Novartis Pharmaceuticals Corporation | $24.77 | 2021 | |
| Novo Nordisk INC | $22.32 | 2024 | Ozempic |
| Actelion Pharmaceuticals US, INC. | $18.42 | 2022 | |
| Amarin Pharma, INC. | $16.51 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $16.47 | 2022 | |
| Agios Pharmaceuticals, INC. | $14.58 | 2022 | |
| Penumbra, INC. | $12.80 | 2022 | |
| Cvrx, INC. | $6.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yazeid Alshebani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.